Nivolumab Plus Bevacizumab for Relapsed Ovarian Cancer
Episode description
According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology. Next, we'll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we'll discuss two recent FDA drug approvals for patients with hematologic disorders.
Coverage of stories discussed this week on ascopost.com:
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
What Is the Best Palliation for End-Stage Lung Cancer?
FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma
FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology.According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology. Next, we'll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we'll discuss two recent FDA drug approvals for patients with hematologic disorders.
Coverage of stories discussed this week on ascopost.com:
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
What Is the Best Palliation for End-Stage Lung Cancer?
FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma
FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Next, we'll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we'll discuss two recent FDA drug approvals for patients with hematologic disorders.According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology. Next, we'll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we'll discuss two recent FDA drug approvals for patients with hematologic disorders.
Coverage of stories discussed this week on ascopost.com:
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
What Is the Best Palliation for End-Stage Lung Cancer?
FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma
FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology. Next, we'll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we'll discuss two recent FDA drug approvals for patients with hematologic disorders.
Coverage of stories discussed this week on ascopost.com:
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
What Is the Best Palliation for End-Stage Lung Cancer?
FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma
FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Nivolumab Plus Bevacizumab in Relapsed Ovarian CancerAccording to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology. Next, we'll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we'll discuss two recent FDA drug approvals for patients with hematologic disorders.
Coverage of stories discussed this week on ascopost.com:
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
What Is the Best Palliation for End-Stage Lung Cancer?
FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma
FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> What Is the Best Palliation for End-Stage Lung Cancer?According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology. Next, we'll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we'll discuss two recent FDA drug approvals for patients with hematologic disorders.
Coverage of stories discussed this week on ascopost.com:
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
What Is the Best Palliation for End-Stage Lung Cancer?
FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma
FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell LymphomaAccording to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology. Next, we'll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we'll discuss two recent FDA drug approvals for patients with hematologic disorders.
Coverage of stories discussed this week on ascopost.com:
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
What Is the Best Palliation for End-Stage Lung Cancer?
FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma
FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia